

IN THE CLAIMS:

Without prejudice or disclaimer, please delete claims 1-9 and add claims 10-23 as follows:

sub
10. A vaccine composition comprising at least one particulate immunogen and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin.

11. The vaccine composition according to claim 10, wherein said B subunits are prepared by recombinant DNA methods.

A *sub B*
12. The vaccine composition according to claim 10 or claim 11, wherein the immunogen comprises a viral antigen, a bacterial antigen, or a fungal antigen, or a combination thereof.

13. The vaccine composition according to claim 10, wherein the immunogen is derived from at least one infective agent which causes a disease which is transmitted by mucosal infection.

14. The vaccine composition according to claim 10, wherein the immunogen is characteristic of a micro-organism which causes a disease which is transmitted by mucosal infection.
15. The vaccine composition according to claim 10 or claim 11, wherein the immunogen provides immunization against a disease which is transmitted by mucosal infection.
16. The vaccine composition according to claim 15, wherein the immunogen comprises influenza antigens.
17. A method for the induction of a systemic immunoglobulin response against an immunogen in a human or animal host in need of such induction, comprising the step of:
administering to mucosal tissue of the host said immunogen in a particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said immunogen together with said B subunits is present in sufficient quantity for said induction.

18. A method for the induction of a common mucosal immune response against an immunogen in a human or animal host in need of such induction, comprising the step of:
- administering to mucosal tissue of the host said immunogen in a particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said immunogen together with said B subunits is present in sufficient quantity for said induction.
19. A method of preparing a vaccine for the induction of a systemic immunoglobulin response against an immunogen in a human or animal host upon mucosal administration of said vaccine, comprising the step of:
- combining said immunogen in a particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said immunogen together with said B subunits is present in sufficient quantity for said induction.
20. A method of preparing a vaccine for the induction of a common mucosal immune response against an immunogen in a human or animal host upon local mucosal administration of said vaccine, comprising the step of:

combining said immunogen in a particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said immunogen together with said B subunits is present in sufficient quantity for said induction.

21. A vaccine comprising at least one particulate immunogen and an adjuvanting amount of B subunits of enterotoxin, wherein said B subunits are free of A subunit and toxic LT holotoxin.

22. A vaccine comprising at least one particulate immunogen and an adjuvanting amount of B subunits of cholera toxin, wherein said B subunits are free of A subunit and toxic CT holotoxin.

23. A vaccine comprising at least one immunogen and an adjuvanting amount of B subunits chosen from enterotoxin and cholera toxin, wherein said B subunits are free of A subunit, toxic LT holotoxin, and toxic CT holotoxin.